Zydus Cadila reduces Remdesivir price to Rs899 for a 100 mg lyophilized injection

Remdac (Remdesivir) India’s most economical Remdesivir brand now made more affordable for patients.

Mar 24, 2021 04:03 IST India Infoline News Service

Cadila Healthcare
In a significant move Zydus Cadila, subsidiary of Cadila Healthcare has made its brand of Remdesivir, Remdac more affordable at Rs899 for a 100 mg lyophilized injection. Remdac which was launched in August 2020 at Rs2800, continues to be India’s most economical brand of Remdesivir and a critical drug in the treatment of COVID-19.

This move to further revise the prices will go a long way in helping patients during these critical times.

Speaking on the development Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited said, “Through the course of this pandemic, our efforts have been focused on making therapies accessible and affordable to people.

Remdac has been one of the critical drugs in the disease management on COVID and we hope that this price cut will enable people from every strata of the society to access this critical drug.”

In June 2020, Zydus entered into a non-exclusive agreement with Gilead Sciences, to manufacture and sell Remdesivir, the investigational drug, which has been issued an Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) to treat patients suffering from severe symptoms of COVID 19.

The API for the drug has been developed and manufactured at the group’s API manufacturing facilities in Gujarat.

Cadila Healthcare ended at Rs426.30 apiece down by Rs4.75 or 1.1% on Sensex.

Related Story

Open Free Demat Account (Rs699)